Audit
Automated checks run on every build (contradictions, sourcing and hygiene) and weekly against the outside world (openFDA labels, ClinicalTrials.gov, and every cited URL). Findings are candidates for review, not verdicts; confirmed errors go to the corrections log.
862
Entities
208
Findings
2
High
52
Medium
0
Older than 60 days
34
Registry mismatches
106
Broken links (gone or unreachable)
221
Refused to the checker (live to readers)
Contradictions
Computed from the corpus alone: status fields that disagree with approval records or the six-region table, positive trials whose primary hazard ratio is not below 1, records last checked before their latest regulatory event, standard-of-care and roadmap rows citing withdrawn items, and future years.
highStandard of care cites a withdrawn or negative item1
| Entity | Kind | Detail |
|---|---|---|
| Pulmonary embolism: ventilation/perfusion imaging | indication | standard-of-care row "Suspected acute pulmonary embolism, intermediate or high pre-test probability, especially pregnancy or contraindication to iodinated contrast" cites Krypton-81m (status historic) without saying so in the text; explain the negative result or drop the reference |
highStatus disagrees with approvals10
| Entity | Kind | Detail |
|---|---|---|
| Iodine-125 brachytherapy seeds | drug | status "approved" but no approvals recorded |
| Ammonia N-13 | drug | US/EU approvals recorded (US 2007) but status is "unset" |
| Choline C-11 | drug | US/EU approvals recorded (US 2012) but status is "established" |
| Flurpiridaz F-18 | drug | US/EU approvals recorded (US 2024) but status is "unset" |
| Iobenguane I-123 (cardiac use) | drug | US/EU approvals recorded (US 2008, US 2013) but status is "unset" |
| Rubidium Rb-82 chloride | drug | US/EU approvals recorded (US 1989) but status is "unset" |
| Technetium Tc-99m pyrophosphate | drug | US/EU approvals recorded (US 1976, US 1976) but status is "unset" |
| Technetium Tc-99m sestamibi | drug | US/EU approvals recorded (US 1990) but status is "unset" |
| Technetium Tc-99m tetrofosmin | drug | US/EU approvals recorded (US 1996, US 1999) but status is "unset" |
| Thallous chloride Tl-201 | drug | US/EU approvals recorded (US 1977, US 1977) but status is "unset" |
mediumMentions a future year77
mediumNumber in the text disagrees with the structured field1
| Entity | Kind | Detail |
|---|---|---|
| ASTRA | trial | text says enrolled 400 but enrolled is 233 |
lowApprovals disagree with the regional table16
| Entity | Kind | Detail |
|---|---|---|
| Abiraterone acetate | drug | regional-approvals.ts records EU approved 2011 but approvals[] has no EU row |
| Cabazitaxel | drug | regional-approvals.ts records EU approved 2011 but approvals[] has no EU row |
| Docetaxel | drug | regional-approvals.ts records EU approved 1995 but approvals[] has no EU row |
| Durvalumab | drug | regional-approvals.ts records EU approved 2018 but approvals[] has no EU row |
| Enzalutamide | drug | regional-approvals.ts records EU approved 2013 but approvals[] has no EU row |
| Everolimus | drug | regional-approvals.ts records EU approved 2009 but approvals[] has no EU row |
| Florbetapir F-18 | drug | regional-approvals.ts records EU approved 2013 but approvals[] has no EU row |
| Flortaucipir F-18 | drug | regional-approvals.ts records EU approved 2024 but approvals[] has no EU row |
| Gallium-68 gozetotide (PSMA-11) | drug | regional-approvals.ts records EU approved 2022 but approvals[] has no EU row |
| Olaparib | drug | regional-approvals.ts records EU approved 2014 but approvals[] has no EU row |
| Pembrolizumab | drug | regional-approvals.ts records EU approved 2015 but approvals[] has no EU row |
| Radioactive iodine (I-131) | drug | regional-approvals.ts records EU approved 1990 but approvals[] has no EU row |
| Radium-223 dichloride | drug | regional-approvals.ts records EU approved 2013 but approvals[] has no EU row |
| Rituximab | drug | regional-approvals.ts records EU approved 1998 but approvals[] has no EU row |
| Sorafenib | drug | regional-approvals.ts records EU approved 2006 but approvals[] has no EU row |
| Sunitinib | drug | regional-approvals.ts records EU approved 2006 but approvals[] has no EU row |
lowApproved product whose linked trials are all still running5
| Entity | Kind | Detail |
|---|---|---|
| Capecitabine | drug | status "approved" but every linked trial is still running (Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: active, A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Durvalumab | drug | status "approved" but every linked trial is still running (TheraSphere With Durvalumab and Tremelimumab for HCC: active, A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Gallium-68 gozetotide (PSMA-11) | drug | status "approved" but every linked trial is still running (PSMA PET Combined With MRI for the Detection of PCa: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Olaparib | drug | status "approved" but every linked trial is still running (FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Temozolomide | drug | status "standard-of-care" but every linked trial is still running (Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: active); link the pivotal trial or note that the approval was accelerated on earlier data |
lowText says approved, status does not3
| Entity | Kind | Detail |
|---|---|---|
| Ammonia N-13 | drug | text mentions approval but status is "unset" |
| Choline C-11 | drug | text mentions approval but status is "established" |
| Fluorothymidine F-18 (FLT) | drug | text mentions approval but status is "phase-2" |
Sourcing
Rule one is cite it. Records with no external source at all, records whose text carries a percentage, hazard ratio, duration or price with no link behind it, and structured trial outcomes without a source.
mediumStructured outcomes without a source12
| Entity | Kind | Detail |
|---|---|---|
| AURORA | trial | 1 of 3 structured outcomes carry numbers without a source: Area under the ROC curve, overall population |
| CONDOR | trial | 1 of 2 structured outcomes carry numbers without a source: Change in intended patient management |
| ENZA-p | trial | 1 of 4 structured outcomes carry numbers without a source: PSA response rate (≥50% decline) |
| FALCON | trial | 1 of 2 structured outcomes carry numbers without a source: Detection rate |
| IDEAS (Imaging Dementia-Evidence for Amyloid Scanning) | trial | 1 of 3 structured outcomes carry numbers without a source: Change in aetiological diagnosis |
| LIGHTHOUSE | trial | 1 of 3 structured outcomes carry numbers without a source: Verified detection rate of distant (M1) lesions |
| LuTectomy | trial | 3 of 4 structured outcomes carry numbers without a source: PSA50 response; Pathological complete response; Grade 3/4 toxicity and Clavien-Dindo grade 3-5 surgical complications |
| OSPREY | trial | 1 of 3 structured outcomes carry numbers without a source: Sensitivity for extraprostatic lesions, Cohort B, vs biopsy |
| POP-RT | trial | 1 of 1 structured outcome carry numbers without a source: Biochemical failure-free survival at 5 years |
| PRINCE | trial | 3 of 4 structured outcomes carry numbers without a source: Objective response rate (RECIST-evaluable subset); Overall survival; Grade 3 immune-related adverse events |
| SPOTLIGHT | trial | 1 of 3 structured outcomes carry numbers without a source: Overall detection rate, all evaluable scans |
| UpFrontPSMA | trial | 2 of 4 structured outcomes carry numbers without a source: PSA progression-free survival; Freedom from castration resistance |
mediumNumbers in the text without a source3
| Entity | Kind | Detail |
|---|---|---|
| MIBG Curie and SIOPEN scores | term | 1 number in the text (10 percent) but no link, Wikipedia page or registry id |
| PSA kinetics: PSA doubling time and PSA density | term | 1 number in the text (50 percent) but no link, Wikipedia page or registry id |
| SDH deficiency (SDHB immunohistochemistry loss) | term | 2 numbers in the text (7 percent, 40 percent) but no link, Wikipedia page or registry id |
lowNo external source6
| Entity | Kind | Detail |
|---|---|---|
| Alpha radioligands after ADC failure | idea | no external link or Wikipedia reference |
| Chris C. Parker | person | no external link or Wikipedia reference |
| MIBG Curie and SIOPEN scores | term | no external link or Wikipedia reference |
| PSA kinetics: PSA doubling time and PSA density | term | no external link or Wikipedia reference |
| SDH deficiency (SDHB immunohistochemistry loss) | term | no external link or Wikipedia reference |
| TROP2 PET | technology | no external link or Wikipedia reference |
Hygiene: orphans and duplicates
Parallel editing leaves seams: records nothing links to, the same name in two kinds, names two characters apart inside a kind, two products with one development code, and spike duplicates whose values diverge (the first copy wins silently). Each row says what a merge would look like.
mediumDuplicate name20
| Entity | Kind | Detail |
|---|---|---|
| Dosimetry | term | same normalised name as f-dosimetry (section) |
| Dosimetry | section | same normalised name as dosimetry (term) |
| Fludeoxyglucose F-18 (brain metabolism) | drug | same normalised name as fludeoxyglucose-f18 (drug) |
| Fludeoxyglucose F-18 (FDG) | drug | same normalised name as f-18-fdg-brain (drug) |
| Iobenguane I-123 | drug | same normalised name as i-123-mibg-cardiac (drug) |
| Iobenguane I-123 (cardiac use) | drug | same normalised name as i-123-mibg (drug) |
| Lutetium-177 dotatate | drug | same normalised name as lu-177-dotatate-generic (drug) |
| Lutetium-177 dotatate (radioligand equivalent) | drug | same normalised name as lutathera (drug) |
| Phosphorus-32 | isotope | same normalised name as phosphorus-32 (drug) |
| Phosphorus-32 (radiophosphorus) | drug | same normalised name as p-32 (isotope) |
| Prostate cancer | indication | same normalised name as prostate-cancer-signalling (pathway) |
| Prostate cancer (KEGG map) | pathway | same normalised name as prostate (indication) |
| Radioembolisation | section | same normalised name as radioembolisation-tare (technology) |
| Radioembolisation (TARE / SIRT, yttrium-90) | technology | same normalised name as f-radioembolisation (section) |
| Radioligand therapy | section | same normalised name as radioligand-therapy (technology) |
| Radioligand therapy (beta emitters) | technology | same normalised name as f-radioligand-therapy (section) |
| Targeted alpha therapy | technology | same normalised name as f-alpha-therapy (section) |
| Targeted alpha therapy | section | same normalised name as targeted-alpha-therapy (technology) |
| Theranostics | term | same normalised name as theranostics-journal (journal) |
| Theranostics | journal | same normalised name as theranostics (term) |
lowSame name in two kinds12
| Entity | Kind | Detail |
|---|---|---|
| Biochemical recurrence of prostate cancer | indication | "psa recurrence" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing |
| mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) | term | "psa recurrence" is also Biochemical recurrence of prostate cancer (prostate-bcr, indication); cross-link them with `related` or merge if they describe one thing |
| mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) | term | "mcrpc" is also Metastatic castration-resistant prostate cancer (prostate-mcrpc, indication); cross-link them with `related` or merge if they describe one thing |
| mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) | term | "mhspc" is also Metastatic hormone-sensitive prostate cancer (prostate-mhspc, indication); cross-link them with `related` or merge if they describe one thing |
| Metastatic castration-resistant prostate cancer | indication | "mcrpc" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing |
| Metastatic hormone-sensitive prostate cancer | indication | "mhspc" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing |
| Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC) | technology | "standardised uptake value" is also Standardised uptake value (SUV) (suv, term); cross-link them with `related` or merge if they describe one thing |
| Radioembolisation (TARE / SIRT, yttrium-90) | technology | "radioembolisation" is also TARE / SIRT (radioembolisation with yttrium-90) (tare, term), Radioembolisation (f-radioembolisation, section); cross-link them with `related` or merge if they describe one thing |
| Standardised uptake value (SUV) | term | "standardised uptake value" is also Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC) (quantitative-imaging-biomarkers, technology); cross-link them with `related` or merge if they describe one thing |
| TARE / SIRT (radioembolisation with yttrium-90) | term | "radioembolisation" is also Radioembolisation (TARE / SIRT, yttrium-90) (radioembolisation-tare, technology), Radioembolisation (f-radioembolisation, section); cross-link them with `related` or merge if they describe one thing |
| Theranostics | term | "theranostics" is also Theranostics (theranostics-journal, journal); cross-link them with `related` or merge if they describe one thing |
| Theranostics | journal | "theranostics" is also Theranostics (theranostics, term); cross-link them with `related` or merge if they describe one thing |
lowOverlapping names2
| Entity | Kind | Detail |
|---|---|---|
| Metastatic castration-resistant prostate cancer | indication | name overlaps with Non-metastatic castration-resistant prostate cancer (prostate-nmcrpc) |
| Non-small cell lung cancer | indication | name overlaps with Small-cell lung cancer (sclc) |
lowOrphan: nothing links here40
| Entity | Kind | Detail |
|---|---|---|
| A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | trial | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | trial | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Trial of HRS-6768 in Patients With Advanced Solid Tumors | trial | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) | trial | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| AHOD2131 (COG / NCTN) | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Annals of Oncology | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment | trial | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Centre Eugène Marquis | institution | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Charité Universitätsmedizin Berlin | institution | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Clinical Cancer Research | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Clinical Nuclear Medicine | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| ClinicalTrials.gov | collection | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| EJNMMI Radiopharmacy and Chemistry | journal | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Folate receptor alpha | target | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Fundación Instituto Valenciano de Oncología (IVO) | institution | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Hamamatsu Photonics | company | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| IDEAS (Imaging Dementia-Evidence for Amyloid Scanning) | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Institut de Cancérologie de l'Ouest (ICO) | institution | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| IRCCS Sacro Cuore Don Calabria Hospital | institution | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Istituto Oncologico Veneto IRCCS | institution | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| JAMA | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Journal of medical imaging and radiation oncology | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Monopar Therapeutics | company | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Nature Medicine | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| NCT/UCC Dresden, University Hospital Carl Gustav Carus | institution | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Nuclear Medicine and Biology | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Payload (ADC) | term | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Pharmacokinetics (PK), half-life and exposure | term | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Radiology | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Science Translational Medicine | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals | paper | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Spectrum Pharmaceuticals | company | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Theranostics | journal | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Tumour hypoxia | term | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Turku University Hospital Cancer Centre | institution | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| University Medical Center Groningen Comprehensive Cancer Center | institution | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
Registry fact checks
Generated 2026-10-19: 93 products checked against openFDA labels, 135 trials against ClinicalTrials.gov (status, phase, primary completion).
Proposed patches
Where the registry value maps unambiguously onto ours, the fact check proposes a concrete edit. Nothing is applied automatically: a maintainer applies each proposed edit by hand, which updates the record, refreshes its checked date and adds a row to the corrections log.
Broken links
Checked 2026-10-21: 1,789 of 1,789 cited URLs probed; 327 did not resolve, 101 redirect to a different domain, 566 have a Wayback Machine copy. Replace a dead URL with the archive copy or a current source; if the fact itself changes, log it in the corrections.
55 links redirect to a different domain
Staleness
Records by last-checked date. The site does not show dates to readers; maintainers use this list to schedule re-checks. What counts as too old for each kind, and which records are past due, is defined on the freshness page.
| Entity | Kind | Last checked | Days |
|---|---|---|---|
| Hepatocellular carcinoma | indication | 2026-09-04 | 51 |
| Neuroendocrine tumours | indication | 2026-09-04 | 51 |
| Thyroid cancer | indication | 2026-09-04 | 51 |
| Astatine-211 alpha therapy | technology | 2026-09-04 | 51 |
| CT (computed tomography) | technology | 2026-09-04 | 51 |
| FAPI PET | technology | 2026-09-04 | 51 |
| FDG PET | technology | 2026-09-04 | 51 |
| HER2 PET | technology | 2026-09-04 | 51 |
| Immuno-PET | technology | 2026-09-04 | 51 |
| Lutetium-177 radioligand therapy | technology | 2026-09-04 | 51 |
| PARP PET | technology | 2026-09-04 | 51 |
| Peptide-drug & small-molecule-drug conjugates | technology | 2026-09-04 | 51 |
| PET (positron emission tomography) | technology | 2026-09-04 | 51 |
| PET/CT | technology | 2026-09-04 | 51 |
| PET/MRI | technology | 2026-09-04 | 51 |
| PSMA PET | technology | 2026-09-04 | 51 |
| Radio-antibody & radio-ADC | technology | 2026-09-04 | 51 |
| Radioligand dosimetry | technology | 2026-09-04 | 51 |
| Radioligand therapy (beta emitters) | technology | 2026-09-04 | 51 |
| Radiomics | technology | 2026-09-04 | 51 |
| Site-specific conjugation & linker chemistry | technology | 2026-09-04 | 51 |
| SPECT & bone scan | technology | 2026-09-04 | 51 |
| Targeted alpha therapy | technology | 2026-09-04 | 51 |
| TROP2 PET | technology | 2026-09-04 | 51 |
| B7-H3 | target | 2026-09-04 | 51 |
| CD20 | target | 2026-09-04 | 51 |
| CEACAM5 | target | 2026-09-04 | 51 |
| DLL3 | target | 2026-09-04 | 51 |
| FAP | target | 2026-09-04 | 51 |
| Folate receptor alpha | target | 2026-09-04 | 51 |
| Glypican-3 | target | 2026-09-04 | 51 |
| HER2 | target | 2026-09-04 | 51 |
| Nectin-4 | target | 2026-09-04 | 51 |
| PARP | target | 2026-09-04 | 51 |
| PSMA | target | 2026-09-04 | 51 |
| Somatostatin receptor 2 | target | 2026-09-04 | 51 |
| TROP2 | target | 2026-09-04 | 51 |
| Actinium-225 PSMA agents | drug | 2026-09-04 | 51 |
| Durvalumab | drug | 2026-09-04 | 51 |
| FAP-2286 (177Lu / 68Ga) | drug | 2026-09-04 | 51 |
| Olaparib | drug | 2026-09-04 | 51 |
| Pembrolizumab | drug | 2026-09-04 | 51 |
| Lutetium-177 vipivotide tetraxetan | drug | 2026-09-04 | 51 |
| Piflufolastat F-18 / Pylarify TruVu | drug | 2026-09-04 | 51 |
| Actinium-225 DOTATATE | drug | 2026-09-04 | 51 |
| Aktis Oncology | company | 2026-09-04 | 51 |
| AstraZeneca | company | 2026-09-04 | 51 |
| Bayer | company | 2026-09-04 | 51 |
| Bristol Myers Squibb | company | 2026-09-04 | 51 |
| Clarity Pharmaceuticals | company | 2026-09-04 | 51 |
| Eli Lilly (incl. Loxo) | company | 2026-09-04 | 51 |
| Fusion Pharmaceuticals (AstraZeneca) | company | 2026-09-04 | 51 |
| GE HealthCare | company | 2026-09-04 | 51 |
| IBA (Ion Beam Applications) | company | 2026-09-04 | 51 |
| ITM Isotope Technologies Munich | company | 2026-09-04 | 51 |
| Johnson & Johnson | company | 2026-09-04 | 51 |
| Lantheus | company | 2026-09-04 | 51 |
| Merck & Co. (MSD) | company | 2026-09-04 | 51 |
| Novartis | company | 2026-09-04 | 51 |
| Orano Med | company | 2026-09-04 | 51 |
| Perspective Therapeutics | company | 2026-09-04 | 51 |
| Pfizer (incl. Seagen) | company | 2026-09-04 | 51 |
| RadioMedix | company | 2026-09-04 | 51 |
| RayzeBio (BMS) | company | 2026-09-04 | 51 |
| Siemens Healthineers | company | 2026-09-04 | 51 |
| SOFIE Biosciences | company | 2026-09-04 | 51 |
| Telix Pharmaceuticals | company | 2026-09-04 | 51 |
| TerraPower Isotopes | company | 2026-09-04 | 51 |
| United Imaging | company | 2026-09-04 | 51 |
| Charité Universitätsmedizin Berlin | institution | 2026-09-04 | 51 |
| Dana-Farber Brigham Cancer Center | institution | 2026-09-04 | 51 |
| Fudan University Shanghai Cancer Center | institution | 2026-09-04 | 51 |
| Heidelberg University Hospital / NCT / DKFZ | institution | 2026-09-04 | 51 |
| Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center | institution | 2026-09-04 | 51 |
| Karolinska University Hospital | institution | 2026-09-04 | 51 |
| LMU Klinikum München | institution | 2026-09-04 | 51 |
| Mayo Clinic | institution | 2026-09-04 | 51 |
| MD Anderson Cancer Center | institution | 2026-09-04 | 51 |
| Memorial Sloan Kettering Cancer Center | institution | 2026-09-04 | 51 |
| National Cancer Institute (NIH) | institution | 2026-09-04 | 51 |
Showing the 80 oldest of 862. Full data: audit.json · factcheck.json · factcheck-patches.json · links.json · freshness · recent changes · corrections log.